Radius Health, Inc.

NasdaqGM:RDUS Stock Report

Market Cap: US$480.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Radius Health Management

Management criteria checks 2/4

Key information

G. Martin

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage17.17%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure6.8yrs

Recent management updates

No updates

Recent updates

Seeking Alpha • Mar 14

Radius Recycling's Surge Justifies A Reevaluation

Summary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Radius Recycling Will Benefit From Steel Tariffs

Summary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Radius Recycling Stays In The Scrap Pile

Summary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Summary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking Alpha
Seeking Alpha • Aug 11

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS).  Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11
Seeking Alpha • Feb 24

Reevaluating Radius Health

Radius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021. Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to. Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive. A full investment analysis follows in the paragraphs below.
Analysis Article • Feb 23

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Analysis Article • Jan 01

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

It is doubtless a positive to see that the Radius Health, Inc. ( NASDAQ:RDUS ) share price has gained some 58% in the...

CEO Compensation Analysis

How has G. Martin's remuneration changed compared to Radius Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$600k

-US$70m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$12mUS$413k

-US$109m

Compensation vs Market: G.'s total compensation ($USD3.49M) is above average for companies of similar size in the US market ($USD2.61M).

Compensation vs Earnings: G.'s compensation has been consistent with company performance over the past year.

CEO

G. Martin (63 yo)

2.3yrs
Tenure
US$3,493,881
Compensation

Mr. G. Kelly Martin has been Executive Chairman of Wren Therapeutics Ltd. since 2018. Mr. Martin serves as the Chief Executive Officer, President and Director at Radius Health, Inc. since April 28, 2020.H...

Leadership Team

NamePositionTenureCompensationOwnership
G. Martin
CEO, President & Director2.3yrsUS$3.49mno data
Danielle Holtschlag
VP of Sales & Head of U.S. Sales Channelsless than a yearUS$741.78kno data
Chhaya Shah
Senior VP & Chief Business Officer2.2yrsUS$1.22m0.27%
$ 1.3m
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno datano datano data
John Potts
Founder & Member of the Scientific Advisory Boardno datano datano data
Michael Rosenblatt
Founderno datano datano data
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno datano datano data
Mark Conley
VP, CFOless than a yearno datano data
Peter Schwartzman
Head of Corporate Financeno datano datano data
Ethan Holdaway
Head of Investor Relationsless than a yearno datano data
Kim Clarke
General Counselless than a yearno datano data
Rohan Lathia
Head of Corporate & Business Developmentless than a yearno datano data
0.8yrs
Average Tenure
61.5yo
Average Age

Experienced Management: RDUS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
G. Martin
CEO, President & Director2.3yrsUS$3.49mno data
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno datano datano data
John Potts
Founder & Member of the Scientific Advisory Boardno datano datano data
Michael Rosenblatt
Founderno datano datano data
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno datano datano data
Jean-Pierre Garnier
Independent Director6.7yrsUS$544.81k0.045%
$ 215.1k
Sean Murphy
Independent Director2yrsUS$534.84k0.012%
$ 55.5k
Willard Dere
Independent Director7.8yrsUS$536.69k0.037%
$ 178.7k
Cecil Richard Lyttle
Chairman of Scientific Advisory Board10.5yrsUS$30.00kno data
Owen Hughes
Independent Chairman9.3yrsUS$832.23k0.034%
$ 163.1k
Catherine Friedman
Independent Director7yrsUS$556.41k0.045%
$ 215.1k
Gary Hattersley
Member of Scientific Advisory Board3.8yrsUS$1.94mno data
6.8yrs
Average Tenure
68.5yo
Average Age

Experienced Board: RDUS's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/08/11 16:11
End of Day Share Price 2022/08/11 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Radius Health, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
John NewmanCanaccord Genuity
Mara GoldsteinCantor Fitzgerald & Co.